-
Sanofi Metadragon receives new indication in China for the treatment of sinus rhythm with a history of atrial fibrillation
Time of Update: 2021-12-24
According to the press release, Maidarone is the only antiarrhythmic drug that has been proven to significantly reduce the risk of hospitalization or all-cause death in patients with atrial fibrillation, providing a long-term effective and safer treatment option for patients with atrial fibrillation .
-
CDE publicly solicits opinions on M7 (R2) related ICH guidelines
Time of Update: 2021-12-24
On December 21, CDE issued an announcement stating that the ICH guideline "M7 (R2): Assessment and Control of Active DNA (Mutogenic) Impurities in Drugs to Limit Potential Carcinogenic Risks" is now in the third stage for comments .
-
Pfizer's $6.7 billion acquisition of Arena, the latter's share price has risen by more than 80%
Time of Update: 2021-12-24
On December 13, Pfizer announced that it had reached a definitive agreement with Arena to acquire all of the latter’s outstanding shares in cash at a price of US$100 per share, with a total transaction value of approximately US$6.
-
The second batch of the 2021 national drug standard improvement project catalog was announced, containing 9 types of pharmaceutical excipients and 2 general testing methods for pharmaceutical packaging materials
Time of Update: 2021-12-24
Drafting of Guidelines for Biological Evaluation and Test Selection of Pharmaceutical Packaging Materials Research purposes research content Drafting of the Method for Determination of Aromatic Primary Amine Extraction in Pharmaceutical Packaging Materials Research purposes research content In order to ensure the smooth progress of the national drug standard improvement work in 2021, the National Pharmacopoeia Commission has made requirements on issues such as subject management .
-
Good news!
Time of Update: 2021-12-24
On December 22, it was reported that Shenzhen Weijiejun Biotechnology Co. , Ltd. (hereinafter referred to as "Unknownjun"), an AI pharmaceutical company focused on intestinal microecological treatmen
-
Blockbuster IMCD China acquires Dike to accelerate the growth of the personal care market
Time of Update: 2021-12-24
Rotterdam, the Netherlands (December 6, 2021) -IMCD NV ("IMCD" or "Company") , the world's leading distributor of specialty chemicals and ingredients, today announced that IMCD China has signed an agreement to acquire Shanghai Dike Fine Chemical Co.
-
Sampling inspections continue to tighten, and a number of pharmaceutical companies have been fined
Time of Update: 2021-12-24
was ordered to make corrections, warned, and fined by the Jiangxi Provincial Food and Drug Administration only in June this year for producing and selling inferior medicines .
-
The State Food and Drug Administration released the 49th batch of generic drug reference preparation catalog
Time of Update: 2021-12-24
On December 8, the State Food and Drug Administration issued an announcement stating that the 49th batch of generic drug reference preparations catalogue was now released after the review and dete
-
The State Food and Drug Administration announces the acceptance of 2 types of traditional Chinese medicines
Time of Update: 2021-12-11
On October 8, the State Food and Drug Administration released information on the acceptance of protection of traditional Chinese medicine varieties.
and Phlegm Heat from Shanghai Kaibao Pharmaceutical Co.
Qing injection, the application items are all renewal .
-
Janssen's IL-12/IL-23 inhibitor submits a new application to the FDA for the treatment of psoriatic arthritis in children
Time of Update: 2021-12-11
Recently, Janssen, a subsidiary of Johnson & Johnson, announced that it has submitted its IL-12/IL-23 inhibitor Stelara (ustekinumab) supplementary biologics license application (sBLA) to the US FDA for the treatment of 5 Children with juvenile psoriatic arthritis (jPsA) over the age of years .
-
Subcutaneous injection!
Time of Update: 2021-12-11
Previously, daratumomab subcutaneous injection has been approved by the FDA in the United States for the treatment of multiple myeloma, light chain (AL) amyloidosis and other indications .
com/us-food-and-drug-administration-approves-darzalex-fasprotm-daratumumab-and-hyaluronidase-fihj-new[3] Genmab Announces Positive Topline Results in Phase III ANDROMEDA Study of Daratumumab in Light-chain (AL) Amyloidosis.
-
Tianyan Pharmaceutical will announce the preclinical data of two transformative antibody projects at the ASH annual meeting
Time of Update: 2021-12-09
Suzhou, China and San Diego, USA November 5, 2021/PRNewswire/ - Tianyan Pharmaceutical (hereinafter referred to as the "Company" or "Tianyan") (NASDAQ: ADAG) is a platform-driven clinic A stage biopharmaceutical company dedicated to discovering and developing new cancer immunotherapies based on original antibodies .
-
Novavax and SII are authorized for emergency use of vaccines in Indonesia
Time of Update: 2021-12-09
(NASDAQ: NVAX), a biotechnology company dedicated to the development and commercialization of next-generation vaccines for severe infectious diseases, and Serum Institute of India Private Limited (SII), the world’s largest vaccine manufacturer, announced today that the National Agency for Medicines and Food Control of the Republic of Indonesia (Badan Peng was Obat dan Makanan (Badan POM)) has granted Novavax the use of Matrix-M™ adjuvant Emergency Use Authorization (EUA) for the recombinant nanoparticle protein new coronary pneumonia vaccine .
-
Bayer joins hands with Jointown to empower self-care and continue to expand the accessibility of health products
Time of Update: 2021-12-09
Both parties agreed to expand the breadth and depth of existing cooperation, and deepen cooperation in areas such as enriching product categories, improving product accessibility, and carrying out self-health science education and publicity, so as to provide consumers with richer self-health solutions to meet diversified needs.
-
TOP10 ophthalmic drugs exposed!
Time of Update: 2021-12-09
According to the latest data from Mi Nei. com, the sales of terminal ophthalmic drugs in public medical institutions in China in 2021H1 exceeded 5 billion yuan, a year-on-year increase of 29.
-
Soaring 20 times!
Time of Update: 2021-12-09
According to CCTV Financial News, Carzodopa sustained-release tablets have been out of stock on the market recently, and many patients have posted in "Parkinson's Bar" to buy drugs from their patients in order to seek medicine .
-
AMX0035 has submitted a new drug application to the FDA for the treatment of amyotrophic lateral sclerosis
Time of Update: 2021-12-09
A few days ago, Amylyx Pharmaceuticals announced that it has submitted a New Drug Application (NDA) for AMX0035 to the US FDA for the treatment of amyotrophic lateral sclerosis (ALS) .
Reference materials:[1] Amylyx Pharmaceuticals Submits New Drug Application (NDA) for AMX0035 for the Treatment of ALS.
-
Soaring 973%!
Time of Update: 2021-12-09
Figure 1: The situation of products declared by Sichuan Guowei for the production of pharmaceuticalsSource: CED official websiteIn recent years, irritable bowel syndrome (IBS) is considered to be a global functional disease with the highest incidence.
-
Supervising the National Medical Insurance Bureau to notify that such medical devices will be discontinued
Time of Update: 2021-12-09
In September of this year, the State Food and Drug Administration, the National Health Commission, and the National Medical Insurance Bureau jointly issued the "Announcement on Doing a Good Job in the Implementation of the Second Batch of Unique Identification of Medical Devices .
-
First-line treatment of NSCLC!
Time of Update: 2021-12-09
ArticleMedicine GuanlanOn November 1, Allis Pharmaceuticals announced that its third-generation EGFR-TKI drug Ivesa (Vometinib mesylate) is the first-line treatment for locally advanced or metastatic non-small cell lung cancer (NSCLC) with sensitive EGFR mutations.
